Impact of Type of Induction Therapy on Outcomes in Older Adults With AML After Allogeneic Stem Cell Transplantation

In a cohort of 127 patients aged ≥60 years who previously received induction therapy with intensive chemotherapy, lower-intensity therapy with or without venetoclax, or underwent allogeneic HSCT in first remission, researchers studied post-HSCT outcomes over a 2-year period. Analysis revealed that lower-intensity therapy with or without venetoclax resulted in lower rates of non-relapse mortality and additionally, type of induction therapy did not significantly impact post-HSCT outcomes.

Access the full article to read more here.